Skip to content
Markets News
Stocks1 min read

Novartis Reports Lower Death Risk in Six-Year Kisqali Study

Makkler Newsroom
October 23, 2026 · Based on reporting by GlobeNewswire, finanzen.net

Six-year NATALEE results showed a 19.1% lower risk of death with Kisqali plus endocrine therapy, while Novartis shares edged lower.

Key takeaways

  • Kisqali plus endocrine therapy reduced the risk of death by 19.1% versus endocrine therapy alone.
  • The absolute overall-survival difference rose to 2.1% at six years from 1.2% at five years.

Novartis said a six-year follow-up of its Phase III NATALEE trial found Kisqali plus endocrine therapy reduced the risk of death by 19.1% compared with endocrine therapy alone. The results covered patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer.

The study included 5,101 patients across 20 countries. Patients had been off Kisqali for a median of 38 months when the latest analysis was conducted. The absolute overall-survival difference between the groups widened to 2.1% at six years from 1.2% at five years.

Novartis said the safety profile remained consistent with earlier analyses, with no new safety signals. As of 14:39 UTC Friday, the shares traded at 127.70 Swiss francs, down 0.92% since the previous close.

Topics
NOVNKisqali

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.